- •Multiparametric MRI can miss a clinically significant prostate cancer.
- •Prostate cancers can be missed if the tumour volume is below 1 cm3.
- •Not all clinically significant prostate cancers can be demonstrated on multiparametric MRI.
Abbreviations:mpMRI (multiparametric magnetic resonance imaging), TRUS (transrectal ultrasound), PI-RADS v2 (the Prostate Imaging–Reporting and Data system version 2), RP (radical prostatectomy), MR-US (magnetic resonance-ultrasound), PSA (prostate-specific antigen), GS (Gleason score), ROI (region-of-interest), ICC (intraclass correlation coefficient)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- MRI-targeted or standard biopsy for prostate-cancer diagnosis.N Engl J Med. 2018; 378: 1767-1777
- Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.Eur Urol. 2014; 66: 22-29
Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet (London, England) 2017; 389 (10071): 815–22.
- Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis.Eur Urol. 2015; 68: 438-450
- Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.J Urol. 2013; 190: 502-508
- Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.J Urol. 2014; 192: 67-74
- A pilot study to evaluate the role of magnetic resonance imaging for prostate cancer screening in the general population.J Urol. 2016; 196: 361-366
- Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies.Eur Urol. 2015; 68: 713-720
- Characteristics of detected and missed prostate cancer foci on 3-T multiparametric MRI using an endorectal coil correlated with whole-mount thin-section histopathology.AJR Am J Roentgenol. 2015; 205: W87-W92
- What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging?.Eur Radiol. 2016; 26: 1098-1107
Mohammadian Bajgiran A, Afshari Mirak S, Shakeri S, et al. Characteristics of missed prostate cancer lesions on 3T multiparametric-MRI in 518 patients: based on PI-RADSv2 and using whole-mount histopathology reference. Abdominal Radiology (New York) 2018.
Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2. Eur Urol 2016; 69(1): 16–40.
- What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.Eur Urol. 2017; 72: 250-266
- Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy.World J Urol. 2009; 27: 271-276
- Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.J Urol. 2007; 178: 1925-1928
Dong F, Jones JS, Stephenson AJ, Magi-Galluzzi C, Reuther AM, Klein EA. Prostate cancer volume at biopsy predicts clinically significant upgrading. The Journal of Urology 2008; 179(3): 896–900; discussion.
- A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.J Urol. 2011; 185: 121-125
- The contemporary concept of significant versus insignificant prostate cancer.Eur Urol. 2011; 60: 291-303
- The percentage of core involved by cancer is the best predictor of insignificant prostate cancer, according to an updated definition (tumor volume up to 2.5 cm3): analysis of a cohort of 210 consecutive patients with low-risk disease.Urology. 2014; 83: 28-32
- PI-RADS version 2: detection of clinically significant cancer in patients with biopsy Gleason score 6 prostate cancer.AJR Am J Roentgenol. 2017; 209: W1-w9
- Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation?.J Urol. 2014; 191: 1272-1279
- Normal central zone of the prostate and central zone involvement by prostate cancer: clinical and MR imaging implications.Radiology. 2012; 262: 894-902
- Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging.Radiology. 2013; 266: 207-217